Avid Bioservices Inc (CDMO)

[pay2play]

Not to beat a dead horse...
http://seekingalpha.com/article/2075263-peregrine-pharmaceuticals-management-discusses-q3-2014-results-earnings-call-transcript

SHAN:
"To that end, we have accomplished a great deal during this past quarter, as the first clinical sites were initiated and with patients already enrolled and being dosed. We also remain on track with our regulatory and ethics approval timeline for rolling out European and Asian-Pacific sites over the next few months."

"Another highlight of the quarter was the receipt of Fast Track designation from the U.S. FDA for the combination of bavituximab and docetaxel to improve overall survival in patients with previously treated non-squamous, non-small cell lung cancer compared to docetaxel alone, which is the indication being examined in the SUNRISE trial. This designation facilitates the development and the review of marketing applications for promising drugs like bavituximab, which are intended to treat serious or life-threatening conditions for indications of unmet medical need."